246 related articles for article (PubMed ID: 9224607)
21. In vitro and in vivo effects of synthetic ribozymes targeted against BCR/ABL mRNA.
Lange W; Cantin EM; Finke J; Dölken G
Leukemia; 1993 Nov; 7(11):1786-94. PubMed ID: 8231247
[TBL] [Abstract][Full Text] [Related]
22. Allosterically controllable maxizymes cleave mRNA with high efficiency and specificity.
Kuwabara T; Warashina M; Taira K
Trends Biotechnol; 2000 Nov; 18(11):462-8. PubMed ID: 11058787
[TBL] [Abstract][Full Text] [Related]
23. [Chronic myelogenous leukemia expressing two bcr-abl chimeric mRNA; a case report].
Hashimoto S; Hiyoshi M; Hino M; Yamane T; Ota T; Koh KR; Tagawa S; Tatsumi N
Rinsho Ketsueki; 1997 Jan; 38(1):72-4. PubMed ID: 9028165
[TBL] [Abstract][Full Text] [Related]
24. Inhibition of chronic myelogenous leukemia cells harboring a BCR-ABL B3A2 junction by antisense oligonucleotides targeted at the B2A2 junction.
Mahon FX; Ripoche J; Pigeonnier V; Jazwiec B; Pigneux A; Moreau JF; Reiffers J
Exp Hematol; 1995 Dec; 23(14):1606-11. PubMed ID: 8542954
[TBL] [Abstract][Full Text] [Related]
25. Ribozyme-mediated cleavage of the BCRABL oncogene transcript: in vitro cleavage of RNA and in vivo loss of P210 protein-kinase activity.
Shore SK; Nabissa PM; Reddy EP
Oncogene; 1993 Nov; 8(11):3183-8. PubMed ID: 8414522
[TBL] [Abstract][Full Text] [Related]
26. Selection of hammerhead ribozymes for optimum cleavage of interleukin 6 mRNA.
Hendrix C; Anné J; Joris B; Van Aerschot A; Herdewijn P
Biochem J; 1996 Mar; 314 ( Pt 2)(Pt 2):655-61. PubMed ID: 8670082
[TBL] [Abstract][Full Text] [Related]
27. An intron promotes the anti-bcr-abl activities of a retrovirally expressed ribozyme in chronic myeloid leukemia cells.
Liu JH; Wu SC; Chen WS; Yen CC; Yang MH; Tsai YC; Chen PM
Biochem Biophys Res Commun; 2004 Jun; 318(3):764-72. PubMed ID: 15144904
[TBL] [Abstract][Full Text] [Related]
28. Design and kinetic analysis of hammerhead ribozyme and DNAzyme that specifically cleave TEL-AML1 chimeric mRNA.
Choi WH; Choi BR; Kim JH; Yeo WS; Oh S; Kim DE
Biochem Biophys Res Commun; 2008 Sep; 374(1):169-74. PubMed ID: 18627769
[TBL] [Abstract][Full Text] [Related]
29. Suppression of BCR-ABL mRNA by various ribozymes in HeLa cells.
Kato Y; Kuwabara T; Toda H; Warashina M; Taira K
Nucleic Acids Symp Ser; 2000; (44):283-4. PubMed ID: 12903379
[TBL] [Abstract][Full Text] [Related]
30. In vivo inhibition by a site-specific catalytic RNA subunit of RNase P designed against the BCR-ABL oncogenic products: a novel approach for cancer treatment.
Cobaleda C; Sánchez-García I
Blood; 2000 Feb; 95(3):731-7. PubMed ID: 10648380
[TBL] [Abstract][Full Text] [Related]
31. Effects of BCR-ABL antisense oligonucleotides (AS-ODN) on human chronic myeloid leukemic cells: AS-ODN as effective purging agents.
Wu AG; Joshi SS; Chan WC; Iversen PL; Jackson JD; Kessinger A; Pirruccello SJ; Sanger WG; Sharp JG; Verbik DJ
Leuk Lymphoma; 1995 Dec; 20(1-2):67-76. PubMed ID: 8750625
[TBL] [Abstract][Full Text] [Related]
32. [Study on the in vitro cleavage abilities of ribozymes specific to different sites of bcr-abl fusion gene and their induction of apoptosis in K562 cells].
Feng Q; Sun B; Zhao Y
Zhonghua Yi Xue Za Zhi; 2000 Feb; 80(2):127-30. PubMed ID: 11798747
[TBL] [Abstract][Full Text] [Related]
33. Chemical and enzymatic probing of effector-mediated changes in the conformation of a maxizyme.
Zhou JM; Nakamatsu Y; Kuwabara T; Warashina M; Tanaka Y; Yoshinari K; Taira K
J Inorg Biochem; 2000 Mar; 78(4):261-8. PubMed ID: 10857905
[TBL] [Abstract][Full Text] [Related]
34. Maxizymes, novel allosterically controllable ribozymes, can be designed to cleave various substrates.
Tanabe T; Takata I; Kuwabara T; Warashina M; Kawasaki H; Tani K; Ohta S; Asano S; Taira K
Biomacromolecules; 2000; 1(1):108-17. PubMed ID: 11709832
[TBL] [Abstract][Full Text] [Related]
35. Unmodified phosphodiester antisense oligodeoxynucleotides to the BCR-ABL junction do not suppress Philadelphia-positive clonogenic cells.
Käbisch A; Pérènyi L; Seay U; Lohmeyer J; Pralle H
Acta Haematol; 1994; 92(4):190-6. PubMed ID: 7701917
[TBL] [Abstract][Full Text] [Related]
36. [The effect of multi-unit ribozymes on the growth inhibition and apoptosis induction of CML K562 cells].
Feng Q; Sun B; Sun K; Shang Z; Wang S; Wang W; Zhao Y; Yan Z; Han W; Zhang Y
Zhonghua Zhong Liu Za Zhi; 2002 Sep; 24(5):435-9. PubMed ID: 12485492
[TBL] [Abstract][Full Text] [Related]
37. Cleavage of full-length beta APP mRNA by hammerhead ribozymes.
Denman RB
Nucleic Acids Res; 1993 Aug; 21(17):4119-25. PubMed ID: 8371986
[TBL] [Abstract][Full Text] [Related]
38. Poor cellular uptake of antisense oligodeoxynucleotides: an obstacle to their use in chronic myeloid leukaemia.
Clark RE
Leuk Lymphoma; 1995 Oct; 19(3-4):189-95. PubMed ID: 8535209
[TBL] [Abstract][Full Text] [Related]
39. Cleavage of BCR-ABL transcripts at the T315I point mutation by DNAzyme promotes apoptotic cell death in imatinib-resistant BCR-ABL leukemic cells.
Kim JE; Yoon S; Choi BR; Kim KP; Cho YH; Jung W; Kim DW; Oh S; Kim DE
Leukemia; 2013 Aug; 27(8):1650-8. PubMed ID: 23434731
[TBL] [Abstract][Full Text] [Related]
40. Alu and translisin recognition site sequences flanking translocation sites in a novel type of chimeric bcr-abl transcript suggest a possible general mechanism for bcr-abl breakpoints.
Martinelli G; Terragna C; Amabile M; Montefusco V; Testoni N; Ottaviani E; de Vivo A; Mianulli A; Saglio G; Tura S
Haematologica; 2000 Jan; 85(1):40-6. PubMed ID: 10629590
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
